UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic …BenzingaThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free su…
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia … – Wall Street Journal
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia …Wall Street JournalThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progres…
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia … – MarketWatch
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia …MarketWatchThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-fre…
UW researchers aim to cure mysterious 'chemo brain' condition – KOMO News
KOMO News |
UW researchers aim to cure mysterious ‘chemo brain’ condition
KOMO News UW researchers aim to cure mysterious ‘chemo brain’ condition. Constance Claussen has experienced cognitive difficulties since going through chemotherapy and a stem cell transplant for multiple myeloma. (Courtesy Constance Claussen.) SEATTLE — Pam … |
U of S labs look at producing cancer fighting antibodies – News Talk 980 CJME
|
U of S labs look at producing cancer fighting antibodies
News Talk 980 CJME An investment of $1.7 million from the federal government’s Western Economic Diversification (WED) and the provincial government helped the lab buy the necessary infrastructure and tools to create the antibodies at a much larger rate. “Anytime we can … |
U of S labs look at producing cancer fighting antibodies – News Talk 650 CKOM
StarPhoenix |
U of S labs look at producing cancer fighting antibodies
News Talk 650 CKOM A lab at the University of Saskatchewan is using their patented technology to generate therapeutic-grade antibodies to treat breast cancer and leukemia. An investment of $1.7 million from the federal government’s Western Economic Diversification (WED … U of S team on the brink of new cancer treatmentStarPhoenix Harper Government and Government of Saskatchewan Invest in New Cancer …Marketwired (press release) University of Saskatchewan gets $1.7M for cancer researchMetroNews Canada |
Project to Use EHRs to Predict Heart Failure in Advance – Health Data Management
MedCity NewsProject to Use EHRs to Predict Heart Failure in AdvanceHealth Data ManagementSutter Health in California and Geisinger Health System in Pennsylvania will join with IBM Corp. to develop data analytics technology that will pull information fr…
Fat-burning supplement OxyElite pulled, linked to liver failure – CNN
Fat-burning supplement OxyElite pulled, linked to liver failureCNN(CNN) — Hawaii health officials are asking stores to pull a fat-burning supplement from shelves after officials linked it to cases of liver failure and acute hepatitis in 29 people. Two…
'Fat-burning' supplement linked to liver failure – WBIR-TV
Parent Herald |
‘Fat-burning’ supplement linked to liver failure
WBIR-TV A bottle of OxyElite Pro purple top. The manufacturer, USAPlabs of Dallas, Texas, has ceased domestic distribution of the supplement “out of an abundance of caution,” the company said. Twenty-nine cases of hepatitis have occurred in Hawaii which may be … Popular Weight-loss Supplement OxyElite Pro Linked to Hepatitis and Liver FailureScience World Report OxyELITE Pro Pulled From Shelves Nationwide After 29 Liver Failure Cases In …Huffington Post Acute liver failure Alert: Hawaii Department of Health asks stores to stop …Legal Examiner Parent Herald –WMBF all 41 news articles » |
ASPS: Soft Tissue Measures Can Optimize Face Transplant – Doctors Lounge
|
ASPS: Soft Tissue Measures Can Optimize Face Transplant
Doctors Lounge … as it can take many months to locate an appropriate donor,” a coauthor said in a statement. “We found that if certain facial measurements were off by as little as 1 millimeter between donor and recipient, they were not the best match for transplant … |